This trial is evaluating whether G-csf will improve 2 primary outcomes and 4 secondary outcomes in patients with Juvenile Myelomonocytic Leukaemias (JMML). Measurement will happen over the course of One year after the transplant date of the last enrolled patient.
This trial requires 140 total participants across 1 different treatment group
This trial involves a single treatment. G-csf is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Common treatments for leukemia and myeloid include chemotherapy, targeted therapy drugs (such as imatinib and sunitinib), phototherapy, stem cell transplantation and more. Stem cells from cord blood is a promising source of hematopoietic stem cells for treating leukemia and myeloid. Antimalarial and antifungal drugs and pyrimethamine can be used to treat myeloid. More studies about these therapeutic modalities are needed." - Anonymous Online Contributor
"MDS/AML arise from hematopoietic stem cells (HSCs) getting errors in their DNA during normal development or through inherited or acquired genetic alterations before or during blood progenitor cell formation. MDS/AML are thought to occur from a malignant clone or myeloproliferative disorder. MDS/AML are characterized by monocytic or megaclonal malignancies often involving chromosome abnormalities. Targeted therapy can improve the overall outcome of patients with MDS/AML." - Anonymous Online Contributor
"Almost 100,000 persons per year will develop leukemias, mainly acute myelogenous leukemia, but also acute lymphoblastic leukemia. The number of leukemias diagnosed during the first year of life is around 25,000 per year." - Anonymous Online Contributor
"Hematological malignancies are a complex group of diseases, which present in different forms and with different symptoms. Hereditary causes of leukemia are also an important component in our concept of disease. They contribute greatly to the etiology of the disease, although the contribution is only partial." - Anonymous Online Contributor
"Chronic myelomonocytic leukemia can be reversed and myeloid leukemias can be cured to at least the extent that they can be prevented, thereby substantially improving the survival and quality of life in this group of patients. The cure can most often be achieved in patients with low to intermediate cytogenetic risk, with a survival of over three years. The disease can be reversed in patients of all ages who are high risk or in refractory cases. Patients are often discharged and may be followed-up at regular intervals, and with careful observation, the disease can be reversed and the patients can eventually be placed on a surveillance program to monitor them for potential relapse." - Anonymous Online Contributor
"Symptoms of acute leukemia include fatigue, loss of appetite, loss of hair, swollen and painful lymph nodes, loss of weight, a fast heart rate and low blood cell counts. Symptoms of chronic leukemia include feeling tired, feeling unsteady on his feet, loss of hair, feeling hot and cold, shortness of breath with physical exertion, weight loss and loss of appetite.\n- What are the signs of myeloid leukemia?\n- What is pneumonia?\nAn pneumonia has four main components. "The first is often pain, often low-grade or none at all, in the chest and usually lasts several days." - Anonymous Online Contributor
"Tcrα-negative/β-negative acute myeloblastic leukemia is uncommon in the pediatric population, but has a very poor prognosis. The absence of Tcrα-positive T cells and/or TCRγ expression has not been defined in other pediatric acute myeloid leukemias. Therefore, the role of Tcrα+ T-cell responses in patients with these pediatric acute myeloid leukemias is unclear. The current standard regimen for treatment of acute myeloid leukemia in the pediatric age group is the induction of remission by the anthracyclines." - Anonymous Online Contributor
"In summary, patients treated with Tcrα/β+ experienced a significant improvement in their HRQOL with respect to baseline scores. Results from a recent paper support the continued investigation of this multimodality approach to myeloid patients suffering from B-CLL or MDS." - Anonymous Online Contributor
"There are many reasons that patients of all ages with leukemia might enroll in a clinical trial, and they need to be informed about the possibility of receiving either a curative or palliative procedure, as well as the risks of having side effects that might be undesirable either for the patient or for others. For each specific patient, the doctors decide how to manage their disease as they see fit." - Anonymous Online Contributor
"We demonstrate that Tcrα/β+ is a distinct entity that is capable of ligation to various cell lineages, and we identify a variety of molecular and cellular targets involved with Tcrα/β+-mediated fusion events including those mediating cell-cell adhesion/migration, oncogene acquisition, and oncogenesis." - Anonymous Online Contributor
"Despite the large number of patients in this study, patients with AML were very unlikely to be a member of a family with a history of the condition. For these reasons, a gene for AML should not be on the list of candidate genes in the AMGL gene, because it would need to have an unusual mode of action that would explain its frequency in patients with AML but very low occurrence in AML-related families, even without the gene itself being a major susceptibility gene." - Anonymous Online Contributor
"Tcrα/β+T cells are an important aspect of natural immunity of T cell receptors. TCRα/β+T cells can kill T cells in their own peripheral tissue. The TCRα/β+T cells are involved in the destruction of myeloid leukemia and some solid tumors. The TCRα/β+T cells can be used as cancer therapeutics. It was an important discovery concerning the use of TCRα/β+ T cells in cancer treatment." - Anonymous Online Contributor